This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Top Stock Reports for JPMorgan Chase, Home Depot & Salesforce
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), The Home Depot, Inc. (HD) and Salesforce, Inc. (CRM).
Avantor (AVTR) Q3 Earnings In-Line With Estimates, Revenues Top
by Zacks Equity Research
Despite Avantor's (AVTR) continued stability in end markets, it reports an overall soft third-quarter performance.
Revvity (RVTY) Misses on Q3 Earnings, Lowers '23 EPS View
by Zacks Equity Research
Revvity's (RVTY) third-quarter results reflect the impact of increased market uncertainty. The company's earnings and sales miss their respective estimates.
Integer Holdings (ITGR) Q3 Earnings Top Estimates, FY23 View Up
by Zacks Equity Research
Integer Holdings' (ITGR) third-quarter results reflect robust Medical Sales, along with strength in the majority of the product lines.
Merit Medical (MMSI) Q3 Earnings Top Estimates, FY23 View Revised
by Zacks Equity Research
Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the third quarter.
DexCom (DXCM) Beats on Q3 Earnings, Raises Sales Outlook
by Zacks Equity Research
DexCom's (DXCM) third-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
CONMED (CNMD) Beats on Q3 Earnings, Ups '23 EPS View
by Zacks Equity Research
CONMED's (CNMD) adjusted third-quarter earnings and sales beat estimates on the back of strong growth in the U.S and international markets. Gross margin improves.
West Pharmaceutical (WST) Beats on Q3 Earnings, HVP Drives Sales
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter results reflect a strong demand for non-COVID-19 demand, especially HVP devices.
Teladoc Health (TDOC) Q3 Loss Narrows on Integrated Care Strength
by Zacks Equity Research
Teladoc Health's (TDOC) Q3 results were aided by membership growth in the Integrated Care unit as well as strong BetterHelp revenues. Management presently expects 2023 net loss per share to be within $1.50-$1.40.
ZBH or ABT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ZBH vs. ABT: Which Stock Is the Better Value Option?
5 Stocks to Watch on Solid Revenues in Last Reported Quarter
by Nalak Das
We have narrowed our search to five U.S. corporate behemoths. These are: JPM, UNH, PG, ABT, FCX.
HCA Healthcare's (HCA) Q3 Earnings Miss on High Expense Level
by Zacks Equity Research
HCA Healthcare's (HCA) Q3 results were hurt by an increase in salaries and benefits expenses. Management presently estimates 2023 EPS to be within $17.80-$18.50, compared with the prior-view of $17.70-$18.90 per share.
Shockwave Medical (SWAV) Announces IVL Studies' Positive Results
by Zacks Equity Research
Shockwave Medical's (SWAV) latest announcement of two new publications validates the utility of IVL in complex nodular and eccentric calcium.
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Company News for Oct 19, 2023
by Zacks Equity Research
Companies In The News Are: PG, ABT, STT, USB.
Geopolitical Conflicts in Middle-East in Focus
by Zacks Equity Research
Geopolitical Conflicts in Middle-East in Focus.
Abbott (ABT) Q3 Earnings and Revenues Surpass, Margins Dip
by Zacks Equity Research
Abbott (ABT) reports solid underlying base business performance in the third quarter of 2023.
Pre-Markets in Red on Mid-East Concerns, Q3 Earnings in Focus
by Zacks Equity Research
U.S. stock futures are trading lower as the geopolitical conflicts between Israel and Palestine-based terrorist group Hamas heightened.
Abbott (ABT) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Abbott (ABT) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 3.64% and 3.60%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Intuitive Surgical (ISRG) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs might have hurt margins.
Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for NOBL
Should You Buy Abbott (ABT) Ahead of Earnings?
by Zacks Equity Research
Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
(ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $90.87 in the latest trading session, marking a +0.75% move from the prior day.
Will Abbott (ABT) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.